Pembrolizumab for Non-Hodgkin's Lymphoma

"Pembrolizumab's safety is rated as a 2. This is due to the lack of efficacy data, as this is only a Phase 2 trial."

"Pembrolizumab is being trialed in 1000 active clinical studies, 122 of which are Phase 3. The majority of these trials take place in Houston, Texas; however, there are 36030 locations running Pembrolizumab trials globally."

"As of July 26th, 2022 this trial is no longer admitting patients. It was initially posted on April 1st, 2015. There are currently 1844 trials for lymphoma and Hodgkin's disease and 1000 trials for Pembrolizumab that are actively recruiting patients."

"Pembrolizumab is a standard treatment for malignant neoplasms. Additionally, this medication can be used to target other conditions like unresectable melanoma and microsatellite instability high."

"This study is not presently looking for new participants. However, it's worth noting that the trial was last updated on 7/26/2022 and initially posted on 4/1/2015. Additionally, there are 1844 other trials related to lymphoma and hodgkins actively recruiting patients as well as 1000 studies concerning Pembrolizumab."

"Currently, there are six sites where this trial is taking place. For example, Beth Israel Deaconess Medical Center in Boston, Memorial Sloan Kettering Cancer Center in New york, and City of Hope National Medical Center in Duarte. There are also three other locations."